Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15%[3] - The net profit attributable to shareholders was RMB 150 million, up 10% compared to the previous year[3] - The company's operating revenue for 2022 was ¥3,969,198,674.06, representing a 16.72% increase compared to ¥3,400,580,726.17 in 2021[18] - Net profit attributable to shareholders reached ¥42,015,206.23, a significant increase of 556.48% from ¥6,400,029.75 in the previous year[18] - The total assets of the company increased by 34.08% to ¥1,591,618,007.45 at the end of 2022, compared to ¥1,187,068,605.90 at the end of 2021[18] - The cash flow from operating activities showed a net increase of 198.89%, reaching ¥152,667,683.61, compared to -¥154,378,944.17 in 2021[18] - The company reported a quarterly revenue of ¥1,286,550,072.47 in Q4 2022, marking a significant increase compared to previous quarters[20] - The company's revenue increased from CNY 3.4 billion in 2021 to CNY 3.969 billion in 2022, representing a year-on-year growth of 16.72%[79] - The net profit attributable to shareholders reached CNY 42.01 million in 2022, a significant increase of 556.48% compared to the previous year[79] Market Expansion and Strategy - The company is focusing on expanding its market presence in the western regions of China, targeting a 25% growth in market share by 2025[3] - Future guidance indicates expected revenue growth of 18% for 2023, driven by new product introductions and market expansion strategies[3] - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of RMB 200 million allocated for this purpose[3] - The company anticipates continued growth in the pharmaceutical distribution market driven by aging population and increased health awareness[28] - The company is focusing on digital transformation and the integration of smart technologies to create a new pharmaceutical supply chain model[35] - The company aims to enhance its supply chain efficiency and establish a comprehensive business channel to support pharmaceutical manufacturers in reaching end markets directly[36] - The company is focusing on enhancing its supply chain advantages and optimizing its product structure based on market demand and consumer behavior[73] - The company plans to enhance its supply chain advantages and optimize warehousing and logistics efficiency to reduce unit costs while increasing terminal sales[142] Product Development and Innovation - New product launches in 2022 included 10 innovative pharmaceutical products, contributing to 30% of total revenue[3] - The company has invested RMB 50 million in R&D for new technologies aimed at improving supply chain efficiency[3] - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing product efficiency[181] - The company aims to build a competitive and sustainable SBBC pharmaceutical service ecosystem through digital innovation and strategic expansion in 2023[141] - The company plans to leverage the MAH system to incubate its own brands and extend its reach upstream in the pharmaceutical supply chain[140] E-commerce and Digital Transformation - The company launched a new online sales platform, Chongqing Yaodamai, which began operations in October 2022, focusing on internet pharmaceutical sales[49] - The e-commerce business revenue increased from 1.495 billion yuan in 2021 to 1.754 billion yuan in 2022, representing a growth rate of 17.32%[63] - The number of effective customers on the e-commerce platform reached 57,100 by the end of 2022, an increase of 10.53% compared to 2021[64] - The company has developed a comprehensive online health media matrix, covering multiple platforms to promote health values and brand awareness[46] - The company is constructing a comprehensive e-commerce matrix centered on its own chain pharmacies and leveraging live-streaming e-commerce[146] Governance and Management - The company has established a sound corporate governance structure[167] - The board of directors consists of 9 members, including 3 independent directors, meeting the legal requirements for composition[161] - The company has implemented a fair and effective performance evaluation and incentive mechanism for senior management, combining base salary with annual performance assessments[166] - The company has undergone significant changes in its board composition, with new appointments aimed at strengthening governance and oversight[175] - The company is focusing on expanding its market presence and enhancing its operational capabilities through strategic appointments and management restructuring[176] Risks and Challenges - The management highlighted risks including intensified market competition and regulatory changes that could impact future performance[3] - The company faces significant risks of failure or substantial initial losses in expanding new businesses, particularly in retail, due to pressures related to talent, management capabilities, and long-term mechanisms[154] - There are ongoing lawsuits related to contract disputes, with uncertain impacts on future profits due to some cases not yet being heard[155] - The company is committed to monitoring industry policy changes to mitigate regulatory risks and enhance direct procurement channels[150] Employee and Compensation - The total number of employees at the end of the reporting period was 1,138, with 648 in the parent company and 490 in major subsidiaries[199] - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to 4.8649 million yuan[187] - The highest individual pre-tax remuneration was received by the financial director, totaling 603.6 thousand yuan[188] - The company has implemented a differentiated compensation incentive policy based on market principles, linking corporate performance to individual work achievements[200] Investment and Fundraising - The company has invested a total of 122.08 million yuan in pre-invested fundraising projects as of March 10, 2021, which will be replaced by fundraising[127] - The company is cautious in implementing the "E-commerce platform optimization and upgrade project," which has led to a slower investment pace compared to the original plan[127] - The company has received independent opinions on the replacement of pre-invested funds, ensuring compliance with regulations[127] - The company utilized up to RMB 34 million of idle raised funds to temporarily supplement working capital for business expansion and daily operations[128]

证券代码：300937 证券简称：药易购 四川合纵药易购医药股份有限公司 投资者关系活动记录表 编号：2023-001 投资者关系活动 □特定对象调研 □分析师会议 类别 □媒体采访 ☑业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及 广大投资者 人员姓名 时间 2023 年 5 月 24 日 15：00-17：00 地点 深圳证券交易所"互动易"平台，云访谈栏目 （http://irm.cninfo.com.cn） 上市公司接待人 董事长：李燕飞女士 员姓名 副董事长、总经理：陈顺军先生 董事会秘书：沈金洋先生 财务总监：郑德强先生 独立董事：邓博夫先生 保荐代表人：罗泽先生 四川合纵药易购医药股份有限公司（以下简称"公司"） 于 2023 年 5 月 24 日举行了 2022 年度网上业绩说明会，本次活 动不涉及应披露的重大信息。针对投资者关心的问题进行了回 投资者关系活动 复，详见深圳证券交易所互动易本次业绩说明会的交流内容。 主要内容介绍 主要问题及回复如下： 1. 根据公告信息，本年度授信总额 5 亿，累计用印余额 3.69 亿，能否披露有哪些银行，利率区间和授信品种？ | ...

关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）《2022 年年度报告》 及摘要已于 2023 年 4 月 21 日在巨潮资讯网（http://www.cninfo.com.cn）上披 露。为使投资者更全面地了解公司《2022 年年度报告》的内容，公司定于 2023 年 5 月 24 日（星期三）下午 15:00-17:00 举行 2022 年度网上业绩说明会，本次 年度业绩说明会将通过深圳证券交易所提供的"互动易"平台举行，投资者可登 录"互动易"网站（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本 次年度业绩说明会。 证券代码：300937 证券简称：药易购 公告编号：2023-032 四川合纵药易购医药股份有限公司 出席本次说明会的人员有：公司董事长李燕飞女士；副董事长、总经理陈顺 军先生；财务总监郑德强先生；董事会秘书沈金洋先生；保荐代表人罗泽先生； 独立董事邓博夫先生等。 2023 年 5 月 18 日 特此公告。 四川合纵药 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 1,121,966,149.54, representing a 23.29% increase compared to CNY 910,012,727.88 in the same period last year[5] - Net profit attributable to shareholders was CNY 31,632,639.16, a significant increase of 246.22% from CNY 9,136,693.85 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 31,478,461.26, up 363.00% from CNY 6,798,768.20 in the previous year[5] - The basic and diluted earnings per share were both CNY 0.33, reflecting a 230.00% increase from CNY 0.10 in the same quarter last year[5] - The net profit for Q1 2023 was CNY 29,507,984.82, a significant increase from CNY 7,414,416.55 in Q1 2022, representing a growth of approximately 297%[23] - The operating profit for the quarter was CNY 34,406,195.40, compared to CNY 9,579,251.88 in the same period last year, indicating a year-over-year increase of about 260%[23] - The total profit for the quarter was CNY 34,387,283.03, compared to CNY 9,656,037.25 in Q1 2022, representing an increase of about 257%[23] - The company reported a total revenue from sales of goods and services of CNY 774,388,431.08, compared to CNY 628,484,597.81 in the same quarter last year, marking an increase of approximately 23%[25] Assets and Liabilities - The company's total assets at the end of the quarter were CNY 1,615,009,586.92, a 1.47% increase from CNY 1,591,618,007.45 at the end of the previous year[5] - Accounts receivable increased by 515.42% to CNY 426,663,455.80, primarily due to sales agreements with wholesale customers[9] - The company reported a 65.19% increase in accounts payable, reaching CNY 306,515,738.89, attributed to higher sales volume[9] - The company's total assets reached ¥1,615,009,586.92, an increase from ¥1,591,618,007.45, showing overall growth[21] - Current liabilities decreased marginally to ¥748,364,046.38 from ¥752,704,099.36, suggesting improved liquidity management[20] - The equity attributable to shareholders increased to ¥843,870,160.41 from ¥813,943,586.42, reflecting a positive change in retained earnings[21] Cash Flow - Cash flow from operating activities was negative at CNY -117,143,342.26, worsening by 103.94% compared to CNY -57,440,183.26 in the same period last year[11] - The net cash flow from financing activities was negative at CNY -106,428,305.48, a decline of 2150.58% compared to CNY 5,190,145.01 in the previous year[11] - Cash and cash equivalents decreased to ¥204,724,673.38 from ¥457,824,436.55 at the beginning of the year, a decline of 55.3%[20] - Total cash and cash equivalents at the end of Q1 2023 were CNY 103,615,786.15, down from CNY 89,292,730.22 at the end of Q1 2022[27] - The cash outflow from investing activities was CNY 9,833,344.66, compared to an inflow of CNY 6,417,422.29 in the same period last year, indicating a shift in investment strategy[27] Shareholder Information - The total number of common stock shareholders at the end of the reporting period is 16,531[14] - The largest shareholder, Li Yanfei, holds 36.97% of the shares, totaling 35,370,000 shares[14] - The second-largest shareholder, Chengdu Biyuan New航创业投资基金, holds 7.11% with 6,800,000 shares[14] - The company has a total of 54,555,100 shares subject to lock-up agreements, with 93,000 shares released during the period[17] - The total number of preferred stock shareholders is not applicable, indicating no preferred shares were issued[16] - The company plans to unlock 25% of the locked shares annually for executives, with the first release scheduled for May 16, 2023[17] - The total number of shares held by the top 10 unrestricted shareholders amounts to 2,616,400 shares[14] - The total number of shares held by the top 10 shareholders with restricted shares remains unchanged at 54,462,100 shares[17] - The company has a lock-up period of 36 months for shares issued during the initial public offering[16] Credit and Impairment - The company experienced a 201.68% increase in credit impairment losses, amounting to CNY -17,887,426.87, due to increased accounts receivable[11] - The company incurred a credit impairment loss of CNY 17,887,426.87, which was higher than the loss of CNY 5,929,230.65 in the previous year[23]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15%[1] - The net profit attributable to shareholders was RMB 150 million, an increase of 10% compared to the previous year[1] - The company's operating revenue for 2022 was CNY 3,969,198,674.06, representing a 16.72% increase compared to CNY 3,400,580,726.17 in 2021[19] - Net profit attributable to shareholders reached CNY 42,015,206.23, a significant increase of 556.48% from CNY 6,400,029.75 in the previous year[19] - The cash flow from operating activities showed a net inflow of CNY 152,667,683.61, a turnaround from a negative cash flow of CNY 154,378,944.17 in 2021, marking a 198.89% improvement[19] - Basic and diluted earnings per share increased to CNY 0.44, up 528.57% from CNY 0.07 in 2021[19] - The total revenue for 2022 reached approximately CNY 3.97 billion, representing a year-on-year increase of 16.72% compared to CNY 3.40 billion in 2021[86] - The revenue from pharmaceutical wholesale (terminal pure sales) accounted for 59.75% of total revenue, amounting to CNY 2.37 billion, with a year-on-year growth of 12.34%[86] - The revenue from pharmaceutical wholesale (commercial distribution) increased by 23.70% year-on-year, totaling CNY 1.54 billion, which represents 38.84% of total revenue[86] User Growth and Market Expansion - User data showed a growth in active users to 5 million, up 20% from 4.2 million in 2021[1] - The company plans to expand its market presence by opening 50 new retail locations in 2023, targeting a 25% increase in market share[1] - The company aims to leverage its logistics capabilities to improve supply chain efficiency, with an investment of RMB 50 million planned for upgrading its logistics infrastructure[1] - The company is actively expanding its business into B2B e-commerce, pharmaceutical wholesale, retail, and new health media sectors, aiming to build a comprehensive digital healthcare ecosystem[39] - The outpatient market is projected to reach a total of 1.6 trillion yuan by 2029, potentially matching or exceeding the inpatient market[32] Research and Development - Research and development expenses increased by 30% to RMB 100 million, focusing on new product development and technological advancements[1] - The company has initiated a drug research and development program, with several products currently undergoing review by the National Medical Products Administration[50] - The company has invested in technology development, focusing on health management, big data, and AI algorithms to strengthen its operational capabilities[72] - The company aims to optimize overall query and statistical speeds, achieving over 90% real-time data collection in its major R&D projects[101] - The number of R&D personnel increased by 8.33% to 117, with a notable rise in master's degree holders by 33.33%[103] Strategic Initiatives and Acquisitions - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of RMB 200 million allocated for this purpose[1] - The company expanded its merger scope by acquiring control of Sichuan Mingyi and other entities, increasing its operational footprint[95] - The company has established partnerships with over 1,800 pharmaceutical manufacturers, securing distribution rights for more than 11,000 drug varieties, including exclusive rights for over 1,100 products[49] - The company has launched a new industrial model, forming strategic partnerships with 29 listed companies and top 100 brands, resulting in nearly 200 proprietary products[50] E-commerce and Digital Transformation - The e-commerce business revenue increased from 1.495 billion yuan in 2021 to 1.754 billion yuan in 2022, representing a growth rate of 17.32%[64] - The number of effective customers on the e-commerce platform reached 57,100 by the end of 2022, an increase of 10.53% compared to 2021[65] - The company established a new C-end operation department in 2022, enhancing its online and offline retail integration[60] - The company has developed a digital health solution leveraging AI and big data, aimed at improving operational efficiency and customer engagement in the pharmaceutical sector[58] - The self-operated e-commerce platform has been upgraded to a platform-level service, improving competitiveness and operational efficiency[102] Regulatory and Compliance - The new regulations for online drug sales, effective December 1, 2022, aim to enhance the supervision and management of online pharmaceutical transactions, indicating a shift towards stricter regulatory compliance[35] - The company has established a comprehensive quality control system in accordance with GSP regulations, but it still faces potential penalties due to quality issues in the production and usage of drugs[154] - The company has implemented a governance structure that complies with relevant laws and regulations, ensuring independent operation from its controlling shareholder[162] - The company has committed to transparent information disclosure, utilizing multiple channels to ensure equal access for all shareholders[166] Corporate Governance - The board of directors has been restructured, now consisting of 9 members, including 3 independent directors, meeting the legal requirements[163] - The supervisory board has been restructured to include 3 members, ensuring compliance with legal requirements and effective oversight of company operations[165] - The company has established a fair and effective performance evaluation and incentive mechanism for senior management[168] - The company emphasizes the protection of stakeholders' rights and interests, promoting mutual benefits[167] - The company is committed to improving its corporate governance structure in line with regulatory requirements[167] Risks and Challenges - The management highlighted risks including intensified market competition and regulatory changes that could impact future performance[1] - The company faces risks from intensified market competition and changing market demands, necessitating a focus on enhancing its strengths and expanding coverage in the outpatient market[150] - The company is currently involved in litigation due to contract disputes, with uncertain impacts on future profits[157] - The company is exploring new business directions including pharmaceutical production licenses, e-commerce, and new retail, aiming for B and C end integration, but faces challenges in talent acquisition and management capabilities[156]

Group 1: Financial Performance and Projections - The company aims to improve profit margins while expanding its scale and optimizing product structure [10] - As of March 31, 2021, the number of shareholders was 29,080 [4] - The company expects stable growth in 2021, with a focus on achieving performance breakthroughs in key areas [5] Group 2: Business Expansion and Strategy - The company has established the "Yao Yi Guo E-commerce Alliance," providing B2B platform and operational experience to over 10 provinces [5][8] - The company plans to expand outside Sichuan, leveraging local partners' resources and supply chain capabilities [4][10] - The company is focusing on both B2B and B2C business models, with ongoing attempts to develop B2C operations [3][7] Group 3: Market Position and Competition - The company is actively working to enhance its competitive edge through digital transformation and integration of online and offline services [4][6] - The company acknowledges the challenges posed by competitors like Alibaba Health and JD Health in logistics [3] - The company is committed to maintaining a balance between market expansion and profitability [10] Group 4: Operational Insights - The company reported a total of 996 franchise stores as of 2020, with 214 new stores added that year [3] - The company is focused on improving customer satisfaction and operational efficiency through restructuring its offline business [4] - The company has a strict management system for accounts receivable, aiming to clear them by year-end [9]

证券代码：300937 证券简称：药易购 编号：2022-001 四川合纵药易购医药股份有限公司 2022 年 4 月 29 日投资者关系活动记录表 | --- | --- | --- | |-------------------------|---------------------------------------|---------------------------------------------------------------------| | | | | | 投资者关系活动 | □特定对象调研 □分析师会议 | | | 类别 | □媒体采访 | 业绩说明会 | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | | | 参与单位名称及 人员姓名 | 参与本次业绩说明会的投资者 | | | | | | | 时间 地点 | 2022 年 4 月 29 | 日 15：00-17 ： 30 网络形式（深圳证券交易所"互动易"平台，云访谈栏目 | | | http://irm.cninfo.com.cn | ） | | 上市公司接待人 | 董事长：李燕飞女士 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥924,379,178.84, representing a 13.72% increase year-over-year[5] - Net profit attributable to shareholders was ¥9,486,511.67, a significant increase of 357.93% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥7,084,081.10, up 262.25% year-over-year[5] - Total operating revenue for the period reached CNY 2,682,648,601.59, an increase from CNY 2,406,228,814.29 in the previous period, representing a growth of approximately 11.5%[18] - The company's net profit attributable to shareholders was CNY 191,403,283.84, up from CNY 174,625,319.88, indicating a growth of approximately 9.5%[18] - The net profit for Q3 2022 was CNY 9,424,419.53, a decrease of 25.4% compared to CNY 12,551,894.93 in Q3 2021[20] - The total profit before tax was CNY 14,443,992.45, a decrease from CNY 14,947,005.30 in the previous year[20] - The operating profit for Q3 2022 was CNY 14,495,605.36, a slight decrease from CNY 15,522,396.67 in the same period last year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,479,874,525.06, reflecting a 24.67% increase from the end of the previous year[5] - Current assets totaled CNY 1,131,433,922.71 as of September 30, 2022, compared to CNY 831,684,671.94 at the beginning of the year, marking an increase of around 36.1%[17] - The company's total assets reached CNY 1,479,874,525.06, up from CNY 1,187,068,605.90, representing a growth of approximately 24.6%[17] - The total liabilities increased to CNY 668,520,864.57 from CNY 399,131,979.12, showing a significant rise of approximately 67.5%[17] - Short-term borrowings increased to CNY 154,180,765.23 from CNY 119,358,790.60, reflecting a rise of about 29.2%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,421[11] - The largest shareholder, Li Yanfei, holds 36.97% of the shares, totaling 35,370,000 shares[11] - The second-largest shareholder, Chengdu Hesen Investment Management Center, holds 7.11% with 6,800,000 shares[11] - The company has a total of 54,850,000 restricted shares remaining after the current period[15] - The company plans to release 100,000 restricted shares on December 21, 2022[15] - The top ten shareholders include four natural persons and six private investment partnerships[11] - The company has not disclosed any related party relationships among the top ten shareholders[11] - The total number of shares held by the top ten unrestricted shareholders is 6,750,000 shares[11] - The company has a lock-up period of 36 months for shares issued in the public offering[14] - The report indicates that there are no shareholders participating in margin trading[12] Research and Development - Research and development expenses for the year-to-date reached ¥13,096,920.83, attributed to the establishment of a new R&D center[9] - The company reported R&D expenses of CNY 13,096,920.83 for the period, highlighting its commitment to innovation and development[18] Cash Flow - The net cash flow from operating activities was CNY 28,978,498.23, a significant improvement from a negative cash flow of CNY -173,221,674.20 in the same period last year[22] - The company reported a net cash outflow from investing activities of CNY -18,791,341.52, an improvement from CNY -34,098,623.56 in Q3 2021[22] - The net cash flow from financing activities was CNY 33,052,442.00, down from CNY 223,989,522.76 in the previous year[22] - The total cash and cash equivalents at the end of the period were CNY 178,364,944.89, an increase from CNY 110,329,420.79 at the end of Q3 2021[22] Financial Expenses - Financial expenses surged by 437.87% to ¥4,010,266.03, driven by increased interest costs from bank loans[9]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,758,269,422.75, representing a 10.35% increase compared to ¥1,593,377,665.06 in the same period last year[22]. - The net profit attributable to shareholders decreased by 18.18% to ¥7,291,452.29 from ¥8,911,217.92 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was ¥4,036,714.41, a significant increase of 196.13% compared to a loss of ¥4,199,285.23 in the same period last year[22]. - The net cash flow from operating activities improved to ¥16,222,366.99, a 111.04% increase from a negative cash flow of ¥146,890,925.21 in the previous year[22]. - Total assets at the end of the reporting period reached ¥1,332,820,810.66, up 12.28% from ¥1,187,068,605.90 at the end of the previous year[22]. - The net assets attributable to shareholders increased slightly by 0.95% to ¥780,865,059.04 from ¥773,508,437.00 at the end of the previous year[22]. - Basic earnings per share decreased by 20.00% to ¥0.08 from ¥0.10 in the same period last year[22]. - Diluted earnings per share also decreased by 20.00% to ¥0.08 from ¥0.10 in the previous year[22]. - The weighted average return on net assets was 0.96%, down from 1.22% in the same period last year[22]. - The operating cost increased to ¥1,629,547,052.36, reflecting an 8.62% rise from ¥1,500,201,360.38 in the previous year[62]. - The gross profit margin for the pharmaceutical wholesale sector increased to 6.25%, up from 8.13% in the previous year[64]. Market Position and Strategy - The company aims to leverage innovative internet and big data technologies to enhance its supply chain efficiency and reduce distribution costs[37]. - The company is focused on the "out-of-hospital" market, aligning with the trend of pharmaceutical distribution shifting from hospitals to community pharmacies and clinics[33]. - The pharmaceutical distribution market is expected to reach RMB 2 trillion by 2026, with a projected CAGR of 4.2% over the next five years[30]. - The company faces increasing competition from both traditional pharmaceutical distributors and e-commerce platforms, necessitating a focus on supply chain integration and customer service[35]. - The company is committed to becoming a leader in the digital health ecosystem, emphasizing technology-driven and sustainable growth strategies[36]. - The company is actively adjusting its organizational structure and management processes to adapt to the competitive pharmaceutical distribution industry[60]. - The company is exploring new business directions in pharmaceutical production licenses, e-commerce, and retail, aiming for a B2C integration strategy, but faces challenges in talent acquisition and management capabilities[99]. E-commerce and Customer Engagement - The e-commerce business revenue grew from 714 million yuan in the first half of 2021 to 837 million yuan in the first half of 2022, representing a growth rate of 17.23%[48]. - The number of effective customers certified by the e-commerce platform exceeded 48,000, a year-on-year increase of 16.40%[48]. - The average monthly active users reached 23,800, a year-on-year increase of 10.67%[48]. - The company has established a comprehensive pharmaceutical product management system, currently managing over 17,000 pharmaceutical products to meet the diverse medication needs of community medical terminals[57]. - The company achieved precise marketing revenue of 377 million yuan in the first half of 2022, a growth of 16.36% compared to the same period in 2021[57]. - The company has introduced a new digital platform aimed at improving customer experience and operational efficiency[188]. Investment and Financial Management - Research and development investment reached ¥8,659,216.61, marking a 100% increase due to the establishment of a new R&D center in the second half of 2021[62]. - The company reported a financial expense increase of 488.34% to ¥2,900,915.70, primarily due to increased interest expenses from bank loans[62]. - The company has implemented an investment management system to mitigate risks associated with new business ventures and is committed to adjusting strategies based on market developments[100]. - The company has not engaged in derivative investments or entrusted loans during the reporting period[86]. - The company has not reported any changes in accounting policies or corrections of prior period errors during this reporting period[190]. Shareholder and Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[5]. - The company emphasizes compliance with the Articles of Association, ensuring shareholder participation in meetings through various legal methods[111]. - The company maintains a commitment to timely, truthful, and accurate information disclosure, avoiding selective disclosure of non-public information[111]. - The company has established a robust investor relations management strategy to ensure fair information dissemination[111]. - The company has fulfilled all commitments made by actual controllers and shareholders during the reporting period[114]. Risks and Challenges - The company faces regulatory risks due to the impact of national healthcare reforms, which have introduced new policies that could increase competition and regulatory pressure in the pharmaceutical distribution sector[95]. - The company has identified a risk in declining demand for cold and antibiotic medications due to ongoing pandemic effects, impacting sales growth[93]. - The company is committed to increasing investments in promotions and research to counteract competitive pressures and market demand fluctuations[93]. - The company is facing intensified market competition and changing market demands, particularly in the outpatient pharmaceutical distribution sector[93]. Future Outlook - The company anticipates a positive outlook for the next fiscal year, with expected revenue growth driven by new product launches[148]. - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion[189]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[189]. - A strategic acquisition of a local competitor is expected to enhance distribution capabilities and increase market penetration[189].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,758,269,422.75, representing a 10.35% increase compared to ¥1,593,377,665.06 in the same period last year[22]. - The net profit attributable to shareholders decreased by 18.18% to ¥7,291,452.29 from ¥8,911,217.92 in the previous year[22]. - The basic earnings per share decreased by 20.00% to ¥0.08 from ¥0.10 in the previous year[22]. - The company reported a 196.13% increase in net profit after deducting non-recurring gains and losses, reaching ¥4,036,714.41 compared to a loss of ¥4,199,285.23 in the previous year[22]. - The gross profit margin increased by 25% compared to the same period last year[38]. - The company achieved sales revenue of 1.758 billion yuan, a year-on-year increase of 10.35%[38]. - The net profit attributable to shareholders was 7.2915 million yuan, a year-on-year decrease of 18.18%[38]. - The company reported a total revenue of 3,312.76 million yuan for the reporting period[122]. - The total revenue for the first half of 2022 was CNY 709.5 million, representing a year-on-year increase of 20.30%[125]. - The company reported a gross profit margin of 21.09% for the same period[125]. Cash Flow and Investments - The net cash flow from operating activities improved significantly, reaching ¥16,222,366.99, compared to a negative cash flow of ¥146,890,925.21 in the same period last year, marking a 111.04% increase[22]. - The company reported a significant increase in financial expenses by 488.34% to ¥2,900,915.70, primarily due to increased interest expenses from bank loans[62]. - The net cash and cash equivalents decreased by 71.32% to ¥16,102,865.42, attributed to reduced net cash flow from financing activities[63]. - The company reported a total of ¥20,680,040.4 in contract liabilities, a decrease of 30.54% from the previous period, indicating a reduction in prepayments from customers[69]. - The company raised CNY 27,625,000.00 from financing activities, a decrease from CNY 303,092,442.69 in the first half of 2021[180]. - The total cash inflow from financing activities was 20,000,000.00 CNY, while the cash outflow was 22,439,625.01 CNY, resulting in a net cash flow of -2,439,625.01 CNY[182]. Assets and Liabilities - Total assets increased by 12.28% to ¥1,332,820,810.66 from ¥1,187,068,605.90 at the end of the previous year[22]. - The company's accounts receivable at the end of the reporting period amounted to ¥280,532,656, representing a 21.05% increase compared to the previous period[69]. - Inventory increased to ¥357,025,777, reflecting a 26.79% rise, attributed to improved operational efficiency and faster inventory turnover[69]. - The total liabilities amounted to ¥267,386,077.96, which is a 20.06% increase compared to the previous period, primarily due to the clearance of accounts payable[69]. - The total amount of financial assets at fair value was reported at ¥22,218,226.56, with a significant increase in the investment in other equity instruments[71]. Market and Competitive Position - The Chinese pharmaceutical distribution market grew from CNY 1.2 trillion in 2017 to CNY 1.6 trillion in 2021, with a compound annual growth rate (CAGR) of 7.5%[30]. - The market is expected to reach CNY 2.0 trillion by 2026, with a projected CAGR of 4.2% over the next five years[30]. - The company ranks 41st in the pharmaceutical distribution industry based on wholesale revenue in 2021[35]. - The pharmaceutical distribution industry is facing increased competition from both traditional and e-commerce platforms, necessitating strategic adaptations[35]. - The company is focusing on expanding its coverage in the outpatient market and integrating various medical resources to strengthen its market position[94]. Strategic Initiatives and Future Plans - The company aims to build a comprehensive F2B2C pharmaceutical service ecosystem, providing a one-stop service system from production to end-users[36]. - The company is committed to becoming a leader in the digital health ecosystem, emphasizing technology-driven and sustainable innovation[36]. - The company plans to enhance its capabilities in drug production licenses, e-commerce, and new retail strategies, aiming for a comprehensive pharmaceutical service ecosystem[94]. - The company has invested in technology research and development in health management, smart warehousing, big data, and artificial intelligence algorithms, aiming to create a leading intelligent decision-making engine[54]. - Future guidance indicates an expected revenue growth of 10-15% for the second half of 2022, driven by new product launches and market expansion efforts[188]. Compliance and Governance - The company emphasizes compliance with the Articles of Association, ensuring shareholder participation in meetings through various legal methods[111]. - The company actively fulfills its tax obligations, ensuring timely tax payments and compliance with tax regulations[112]. - The company has established a comprehensive human resources management system, including detailed regulations on employee onboarding, training, compensation, and benefits[111]. - The company has committed to not transferring or entrusting shares for 12 months post-IPO, ensuring stability in shareholding[114]. - The company has not faced any environmental penalties during the reporting period and continues to uphold its corporate social responsibility commitments[110].